'Aberrations In Value' Can Help Biotech Pull In Global Funding March 28, 2005 By Brady Huggett LONDON - Jonathan Kil, president and CEO of Sound Pharmaceuticals Inc., is looking for a considerable first round of funding - as much as $40 million, although that might be done in tranches, with a first closing for $10 million.Read More
Coley Gets $50M Up Front In ProMune Alliance With Pfizer March 25, 2005 Coley Pharmaceutical Group Inc. entered a deal with Pfizer Inc. worth up to $505 million for its lead cancer drug, ProMune. (BioWorld Today)Read More
RSS